Drugs / Affitope AD01
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00495417 Comparator | Jul 2007 → Aug 2009 | Alzheimer disease | Affiris AG | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Affitope AD01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00495417 ↗ |
| Route | Subcutaneous | “repeated once every 4 weeks administration by subcutaneous injection of Affitope AD01 alone or adsorbed to aluminum hydroxide” NCT00495417 ↗ |